Up next

Future-Proofing the Pharma Customer & Supplier Relationship

The US Supreme Court ruling on reciprocal tariffs is the latest turn in a fluid global trade situation. How can pharma companies and their suppliers adapt? An executive panel at DCAT Week will share ways on how they are collaborating.

The US Supreme Court ruling on reciprocal tariffs is the latest turn in a fluid global trade situation. How can pharma companies and their suppliers adapt? An executive panel at DCAT Week will share ways on how they are collaborating.

Continuous adaption
Evolving US tariff/trade policy is but one of the many variables that bio/pharmaceutical companies and their suppliers are facing. Global supply chains are always subject to geopolitical uncertainties, fluctuating economic conditions, and changes in trade and government policies, but the pace of that change has accelerated. Add to that the base challenge of increased product and supply chain complexity in the industry, and the need for bio/pharma companies and their suppliers to adapt is ever more important for supply assurance.

Xavier De Ceuninck, Category Management Lead, PGS Global Procurement, Source to Pay, Pfizer

An executive panel at the DCAT Week program, Future-Proofing the Pharma Customer–Supplier Relationship, will share lessons learned, best practices, and innovative ways on how they are collaborating to enhance supply-chain visibility and resilience, mitigate risk, and optimize supply planning now and for what may lie ahead.

Troy Mathews, Executive Director, Direct Materials Strategic Sourcing, Supplier Management & Site Operations, Global Procurement – Global Product Development & Supply, Bristol Myers Squibb

Participating in the panel of are:  Xavier De Ceuninck, Category Management Lead, PGS Global Procurement, Source to Pay, Pfizer; Emad Abdelsadek, Vice President, Sales, EMEA, BD Biopharma Systems; Troy Mathews, Executive Director, Direct Materials Strategic Sourcing, Supplier Management & Site Operations, Global Procurement – Global Product Development & Supply, Bristol Myers Squibb; and Sara Henneman, Vice President and General Manager, Cell Culture and Cell Therapy, Thermo Fisher Scientific. The panel will be moderated by Vishal Bhandari, Partner, Healthcare & Life Sciences Practice, Americas, Kearney.

The program, Future-Proofing the Pharma Customer–Supplier Relationship, is part of DCAT Week, the premier gathering for companies engaged in the global bio/pharmaceutical business ecosystem, hosted by the Drug, Chemical & Associated Technologies Association (DCAT). DCAT Week will be held March 23–26, 2026, in New York. The program, Future-Proofing the Pharma Customer–Supplier Relationship, will be held on Tuesday March 24, 2026, 11:00 AM–12:00 PM. Further information, including how to register, may be found here. The program is exclusive to DCAT Member Companies.

Recent Feature Articles

A New Round in US Pharma Tariffs: What’s at Play?

By
President Trump announced this week a phased plan to impose tariffs on imported generic drugs into the US as a means to encourage US-based production of generics, and a previously announced executive action for tariffs on patented drugs is coming due. 

In Vivo Cell Therapies: Solving Mfg Obstacles?

By
Several bio/pharma majors are making a play in in vivo cell therapies with recent $1-billion-plus acquisitions with an aim for both clinical and manufacturing benefits. Are in vivo cell therapies the up-and-coming segment in advanced therapies?

J&J Aims To Be $100-Bn Company; Begins Supply-Chain Restructuring

By
Johnson & Johnson is aiming to cross the $100-billion revenue mark in 2026 and is beginning a multi-year supply-chain restructuring program in its Innovative Medicine segment.

Solid Dosage Drugs: Keeping Pace in New Drug Approvals

By
Solid dosage drugs are a steady segment in the global bio/pharma industry, but how do they measure in new drug approvals? A look at the dosage forms of new drug approvals thus far in 2026 and the market potential of some key solid dosage drugs.